EUVIMEDEUVIMED entdecken
Open Access

CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients

Imran J Anwar iD, Isabel DeLaura iD, Joseph M Ladowski iD, Davide Schilirò iD, Qimeng Gao iD, Miriam Manook iD, Janghoon Yoon iD, Rafaela Belloni iD, Angela Park iD, Daniel J Schuster iD, Mingqing Song iD, Lin Lin iD und 5 weitere

Science Translational Medicine · 2025-01 · 17 (779)

DOI: 10.1126/scitranslmed.adn8130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2025-01. Verfasst von Imran J Anwar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, CD40 Ligand, Graft Rejection, Antibodies, Monoclonal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current desensitization and maintenance immunosuppression regimens for kidney transplantation in sensitized individuals show limited ability to control the posttransplant humoral response, resulting in high rates of antibody-mediated rejection (ABMR) and graft failure. Here, we showed that anti-CD154 monoclonal antibody (mAb)–based immunosuppression more effectively controlled allograft rejection and humoral rebound in a highly sensitized nonhuman primate kidney transplantation model compared with tacrolimus-based standard-of-care (SOC) immunosuppression. Desensitization with an anti-CD154 mAb (5C8) and a proteasome inhibitor led to decreased donor-specific antibodies (DSAs) and disruption of lymph node germinal centers with reduction of proliferating, memory, and class-switched B cells as well as T follicular helper cells. After transplant, the nonhuman primates maintained on 5C8-based immunosuppression had significantly better survival compared with those maintained on SOC immunosuppression (135.2 days versus 32.8 days, P = 0.013). The 5C8-treated group demonstrated better suppression of DSAs after transplant, more robust suppression of B cell populations, and better induction of regulatory T cells. Fewer infectious and welfare complications, including viral reactivation and weight loss, were also observed with 5C8-based immunosuppression compared with SOC immunosuppression. Therefore, anti-CD154 mAbs may improve kidney transplant outcomes through better control of posttransplant immune responses. The superior efficacy of anti-CD154 mAb–based immunosuppression over tacrolimus-based SOC seen in this highly sensitized NHP transplant model suggests that anti-CD154 mAbs could potentially be used to desensitize and treat highly sensitized patients receiving kidney transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationCD40 LigandGraft RejectionAntibodies, MonoclonalAnimalsB-LymphocytesImmunosuppressive AgentsGerminal CenterTransplant RecipientsGraft SurvivalTacrolimusMaleImmunosuppression TherapyT-Lymphocytes, Regulatory

Substanzen

CD40 LigandAntibodies, MonoclonalImmunosuppressive AgentsTacrolimus

Autor:innen und Institutionen

  • Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
  • Department of Biostatistics & Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA.
  • Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Nonhuman Primate Reagent Resource, UMass Chan Medical School, Worcester, MA 01605, USA.

ORCID-Profile: Imran J Anwar, Isabel DeLaura, Joseph M Ladowski, Davide Schilirò, Qimeng Gao, Miriam Manook, Janghoon Yoon, Rafaela Belloni, Angela Park, Daniel J Schuster, Mingqing Song, Lin Lin, Alton B Farris, Diogo Magnani, Jean Kwun, Stuart J Knechtle

Förderung

  • NIAID NIH HHS

Zitieren

APA

Anwar, I. J., DeLaura, I., Ladowski, J. M., Schilirò, D., Gao, Q., Manook, M., Yoon, J., Belloni, R., Park, A., Schuster, D. J., Song, M., Lin, L., Farris, A. B., Magnani, D., Williams, K., Kwun, J., & Knechtle, S. J. (2025). CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients. Science Translational Medicine, 17(779). https://doi.org/10.1126/scitranslmed.adn8130

Vancouver

Anwar IJ, DeLaura I, Ladowski JM, Schilirò D, Gao Q, Manook M, et al. CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients. Science Translational Medicine. 2025;17(779). doi:10.1126/scitranslmed.adn8130

BibTeX
@article{Anwar2025,
  author = {Anwar, Imran J and DeLaura, Isabel and Ladowski, Joseph M and Schilirò, Davide and Gao, Qimeng and Manook, Miriam and Yoon, Janghoon and Belloni, Rafaela and Park, Angela and Schuster, Daniel J and Song, Mingqing and Lin, Lin and Farris, Alton B and Magnani, Diogo and Williams, Kyha and Kwun, Jean and Knechtle, Stuart J},
  title = {CD154 blockade effectively controls antibody-mediated rejection in highly sensitized nonhuman primate kidney transplant recipients},
  journal = {Science Translational Medicine},
  year = {2025},
  volume = {17},
  number = {779},
  doi = {10.1126/scitranslmed.adn8130}
}
Kostenlos starten →